Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 18/20 | 0.46 |
| ▸ | RARB | P10826 | 13/20 | 0.43 |
| ▸ | RARG | P13631 | 12/20 | 0.39 |
| ▸ | RARA | P10276 | 8/20 | 0.39 |
| ▸ | RXRB | P28702 | 9/20 | 0.39 |
| ▸ | RXRG | P48443 | 8/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6833604 | 1.00 | RXRA (0.46) | RXRARARBRARGRARARXRB | |
| SCHEMBL7568695 | 0.84 | RXRA (0.53) | RXRARARBRARGRARARXRB | |
| SCHEMBL6833636 | 0.77 | RXRA (0.58) | RXRARARBRARGRARARXRB | |
| SCHEMBL6833639 | 0.77 | RXRA (0.58) | RXRARARBRARGRARARXRB | |
| SCHEMBL6950903 | 0.74 | RXRA (0.56) | RXRARARBRARGRARARXRB | |
| SCHEMBL6950912 | 0.74 | RXRA (0.56) | RXRARARBRARGRARARXRB | |
| SCHEMBL6257239 | 0.74 | RXRA (0.56) | RXRARARBRARGRARARXRB | |
| SCHEMBL12418592 | 0.74 | RXRA (0.51) | RXRARARBRARGRARARXRB | |
| SCHEMBL726366 | 0.74 | RXRA (0.59) | RXRARARBRARGRARARXRB | |
| SCHEMBL15347776 | 0.72 | RXRA (0.50) | RXRARARBRARGRARARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040049072-A1 | RXR modulators with improved pharmacologic profile | LIGAND PHARMACEUTICALS INC | 2004-03-11 | — | — | US | disclosed |
| US-6593493-B1 | 2-(Carboxy(unsaturated)alkyl)-1-(haloalkoxy)benzene derivatives; retinoid X receptors; cardiovascular, skin, eating and vision disorders; anticarcinogenic agents; non-insulin-dependent diabetes | LIGAND PHARMACEUTICALS, INC. | 2003-07-15 | — | — | US | disclosed |
| EP-1216221-A2 | RXR MODULATORS WITH IMPROVED PHARMACOLOGIC PROFILE | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2002-06-26 | — | — | EP | disclosed |
| WO-2001019770-A2 | RXR MODULATORS WITH IMPROVED PHARMACOLOGIC PROFILE | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2001-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040049072-A1 | RXR modulators with improved pharmacologic profile | RXRB, RXRG, RXRA | RXRA 3/4885RARB 19/4885RARG 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.